

Cell Kinetics and siSTEAP4 Responses

Ceren Gonen

Ege University Pharmacy Faculty Pharmacology Dept. Bornova, Izmir, Türkiye

ABSTRACT

STAMP family genes STAMP1/STEAP2 and STAMP2/STEAP4 have only expressed in androgen receptor-positive cells, the role of AR in STAMP family gene expression is an important question.

Keywords: STAMP2, STEAP4, LNCaP, Tyripan blue.

Highlights:

1. Transfection of STEAP genes to DU145 and PC3 cells.
2. Androgen induction to LNCaP cells
3. Gene silencing of STEAP4
4. Amplification of apoptosis related genes.

INTRODUCTION

Prostate cancer is cancer of the prostate. The prostate is a gland in the male reproductive system that surrounds the urethra just below the bladder. Most prostate cancers are slow growing. Cancerous cells may spread to other areas of the body, particularly the bones and lymph nodes. Globally, it is the second-most common cancer. It is the fifth-leading cause of cancer-related death in men.] In 2018, it was diagnosed in 1.2 million and caused 359,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. One study reported prostate cancer in 30% to 70% of Russian and Japanese men over age 60 who had died of unrelated causes. Scientists have established prostate cancer cell lines to investigate disease progression. LNCaP, PC-3 (PC3), and DU-145 (DU145) are commonly used prostate cancer cell lines. The LNCaP cancer cell line was established from a human lymph node metastatic lesion of prostatic adenocarcinoma. PC-3 and DU-145 cells were established from human prostatic adenocarcinoma metastatic to bone and to brain, respectively. LNCaP cells express AR, but PC-3 and DU-145 cells express very little or no AR. The proliferation of LNCaP cells is androgen-dependent but the proliferation of PC-3 and DU-145 cells is androgen-insensitive. We searched for prostate-specific genes expressed in the early stages of prostate cancer. In one project we came across a gene with six transmembrane domains at its C-terminus (six transmembrane protein of prostate1, STAMP1) (Korkmaz KS., 2002) and later STAMP2 (Korkmaz CG., 2005) and STAMP3 were identified.

Scientists have established prostate cancer cell lines to investigate disease progression. LNCaP, PC-3 (PC3), and DU-145 (DU145) are commonly used prostate cancer cell lines. The LNCaP cancer cell line was established from a human lymph node metastatic lesion of prostatic adenocarcinoma. PC-3 and DU-145 cells were established from human prostatic

adenocarcinoma metastatic to bone and to brain, respectively. LNCaP cells express AR, but PC-3 and DU-145 cells express very little or no AR. The proliferation of LNCaP cells is androgen-dependent but the proliferation of PC-3 and DU-145 cells is androgen-insensitive. We searched for prostate-specific genes expressed in the early stages of prostate cancer.

RESULTS

The apoptotic activity that was investigated following the transfer of STAMP genes; typical morphological changes, cell death/cell growth were followed by a standard method, Trypan Blue/Trypan Blue counting. The growth kinetics of DU145 and PC3 cells transfected with FuGENE HD with HisMax-vector, HisMax-STAMP1, HisMax-STAMP2 and HisMax-STAMP3 plasmids were determined by trypsinizing the cells after 48 hours of transfection, seeding them at 10,000 cells/ml and counting them with Trypan Blue for 12 days. Cells were seeded in 1ml in 12-well plates and on the following 2nd, 4th, 6th, 8th, 10th and 12th days, cells were examined under a microscope and cell counts were made with the addition of Trypan Blue.




Figure 1 shows the kinetics of DU145 and PC3 cells transfected with HisMax-STAMP1, HisMax-STAMP2 and HisMax-STAMP3.

As shown in the figure, HisMax-STAMP3 transfected cells in both cell lines showed lower growth kinetics compared to HisMax-vector. HisMax-STAMP1 transfection showed a similar picture to HisMax-vector transfection in DU145 cells, while an increased proliferation was detected in PC3 cells on day 10. Both HisMax-STAMP2 transfected cell lines showed a trend

toward increased expression compared to HisMax-vector transfected cells. Amplification of STAMP2-siRNA (h):sc-89820 Santa Cruz Biotechnology Inc. (Bergheimer, Germany) in LNCaP cells: For STAMP2, the efficiency of silencing was examined in day 1, 2, and 5 samples with specific primers (Figure 2)




Figure 2: LNCaP cells STAMP2-siRNA treatment. ANOVA followed by Tukey's Multiple Comparison Test C+ vs siRNA+1 aP < 0.001, C+ vs siRNA+2 aP < 0.001, C+ vs siRNA+5 aP < 0.001, siRNA+1st day vs siRNA+5th day bP < 0.05

In the amplifications performed using specific primers for STAMP2 1st, 2nd and 5th day siRNA samples against the control, the 5th day was accepted as the day with the most ideal silencing, For STAMP2, androgen-R1881 induction was performed (Figure 3).






Figure 3: LNCaP cells androgen- R1881 induction.

Paired Samples T Test: C- vs C+, aP < 0.05, n = 3 Increased STAMP2 expression was shown with androgen induction in cells.



Apoptosis panel was applied in +/- androgen-R1881 induction, control and siRNA groups (Figure 4).



(B)

Figure 4: LNCaP cells in control and R1881 induction (A) and STAMP2-siRNA (B) application

In Figure 4-A, application of synthetic androgen-R1881 to LNCaP cells decreased the expression of androgen proapoptotic and apoptotic genes, but the p53 inhibitor caused a 4.3-fold increase in MDM2. However, STAMP2-siRNA application in Figure 4-B did not cause any change in the apoptosis panel. Androgen induction and STAMP2-siRNA androgen comparison were performed (Figure 5).




Figure5: LNCaP cells Androgen induction and STAMP2-siRNA+ androgen comparison STAMP2-siRNA group was compared with R1881 + STAMP2-siRNA group (Figure 5).

Although no change in response was observed with siRNA application, androgen application and synthetic androgen-R1881 caused a decrease in androgen proapoptotic and apoptotic gene expressions, but the p53 inhibitor caused an increase in MDM2 response. At this point, androgen regulation of STAMP2 plays an important role.

DISCUSSION

Prostate cancer is the second most common type of cancer in men worldwide today. Despite advances in diagnosis, follow-up and treatment, prostate cancer is a highly heterogeneous disease. By regulating some genes involved in the cell cycle, STAMP1 causes cycle arrest in the G0 - G1 phase. The proliferative activities of STAMP1 appear to be related to the ERK (extracellular signal-regulated kinase) pathway. Other members of the STAMP family include pHyde, a rat homologue that has been implicated in the apoptosis of prostate cancer cells, and its human homologue TSAP6 (also known as STEAP3), a p53-inducible gene involved in apoptosis and the cell cycle in prostate cancer and HeLa cells. • Studies reported that STAMP family members have metalloredutase activities associated with iron and copper uptake into HEK-293T cells though mentioned activities have been shown for prostate cells

ACKNOWLEDGEMENT

This study was supported by grants from the Scientific and Technological Research Council of Türkiye (TUBITAK) to CGK (Grant no.: 106S295) and the Turkish Academy of Sciences (TUBA) to CGK (GEBIP-2007).

Conflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper

Statistical Analysis

All results represent one of at least three independent experiments with similar outcomes. All data are expressed as the mean $\pm$ standard error of mean. One-way analysis of variance (ANOVA) and Tukey post hoc test were used to compare groups of data. $P \leq 0.05$ was considered to indicate a statistically significant result. GraphPad Software, Version 4.03 (San Diego, CA, USA) was used for the statistical analysis.

Abbreviations

MDM2	E3 ubiquitin ligase
STEAP	six transmembrane epithelial antigens of prostate
STAMP	six transmembrane protein of prostate
TUBA	Turkish Academy of Sciences
TUBITAK	The Scientific and Technological Research Council of Türkiye

References

BRUCKHEIMER, E. M. and Kyprianou, N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. *Cell Tissue Res*, 301(1), 153-62 (2000).

CRAWFORD, E.D., Rosenblum, M., Ziada, A.M. and Lange, P.H. Hormone refractory prostate cancer. *Urology*, 54, 1-7 (1999).

ENGEDAL N., Korkmaz C.G., Saatcioglu F., C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. *Oncogene*, 2002; 21(7): 1017-27.

FULDA S. Evasion of apoptosis as a cellular stress response in cancer. *Int J Cell Biol*. V 2010:370835. Epub Feb 18 (2010).

GONEN C. (2024). PMA induction to Prostate Cancer Cell Lines: DU145 and LNCaP. *British Journal of Healthcare and Medical Research*. Vol. 11, No:5, 82-94

GONEN C. Promoter Region Analysis of STAMP1/STEAP2 Gene-Silencing of STAMP1/STEAP2 Gene Triggers P53 Upregulation *CellBio* > Vol.12 No.1, March 2023

HSING AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? *Cancer Epidemiol Biomarkers Prev*. 17(10):2525-30 (2008).

HUBERT RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. *Proc Natl Acad Sci U S A*. 1999 Dec 7;96(25):14523-8(1999).

HUGGINS, C. and Hodges, C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of

the prostate. 1941. *J Urol*, 167, 948-951; discussion 952 (2002).

KORKMAZ, C.G., Korkmaz, K.S., Kurys, P., Elbi, C., Klock, T.I., Hammerstram, C., Svindland, A., Hager, G.L. and Saatcioglu, F. Molecular cloning and characterization of STAMP2, an androgen regulated six-transmembrane protein that is overexpressed in a subset of prostate cancers. *Oncogene*. 21; 24(31):4934-45 (2005).

KORKMAZ, K.S., Elbi, C., Korkmaz, C.G., Loda, M., Hager, G.L. and Saatcioglu, F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. *J Biol Chem*, 277, 36689-36696 (2002).

MOLDES, M., Lasnier, F., Gauthereau, X., Klein, C., Pairault, J., Fève, B. and Chambaut-Guerin, A.M. Tumor necrosis factor- α -induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor- α and adipose conversion. *J Biol Chem*, 276, 33938-33946 (2001).

OHGAMI RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE, Fleming MD. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. *Nat Genet*;37(11):12649 (2005).

ORDOVAS, J.M. ABC1: the gene for Tangier disease and beyond. *Nutr Rev*, 58, 76-79 (2000).

PASSER BJ, Nancy-Portebois V, Amzallag N, Prieur S, Cans C, Roborel de Climens A, Fiucci G, Bouvard V, Tuynder M, Susini L, Morchoisne S, Cribble V, Lespagnol A, Dausset J, Oren M, Amson R, Telerman A. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. *Proc Natl Acad Sci U S A*;100(5):2284-9. Epub 2003 Feb 26 (2003).

POMMIER, Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer*, 6(10), 789-802 (2006).

ROOS WP, Kaina B. DNA damage-induced cell death by apoptosis. *Trends Mol Med*. Sep;12(9):440-50. Epub 2006 Aug 8. Review (2006).

SRIKANTAN V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava

S. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer Proc Natl

Acad Sci U S A.;97(22):12216-21(2000).

STEINER MS, Zhang X, Wang Y, Lu Y. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. Cancer Res.15;60(16):4419-25(2000).

TAMURA T., Chiba J. (2009) STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells Int.J.Mol.Med. 24: 599- 604

TUSNADY GE, Bakos E, Varadi A, Sarkadi B. Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters. FEBS Lett. Jan 27; 402(1):1-3(1997).

XU, L.L., Su, Y.P., Labiche, R., Segawa, T., Shanmugam, N., McLeod, D.G., Moul, J.W. and Srivastava, S. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer, 92, 322-328 (2001).

Table 1: Genes and primers used as an apoptosis panel for quantitative polymerase chain reaction (qPCR) analysis

GenBank/Symbol	Description	Gene name	Primer sequence
NM_005163/AKT1	V-akt murine thymoma viral oncogene homolog 1	PKB/PRKBA	Forward: TCCCCCTCAGATGATCTCTCCA Reverse: CGGAAAGGTTAAGCGTCGAAAA
NM_001227/CASP7	Caspase 7, apoptosis-related cysteine peptidase	CMH-1/ICE-LAP3	Forward: AAGTGAGGAAGAGTTTATGGCAA A Reverse: CCATCTTGAAAACAAAGTGCCAAA
NM_001229/CASP9	Caspase 9, apoptosis-related cysteine peptidase	APAF-3/APAF3	Forward: TCCTGAGTGGTGCCAAACAAAA Reverse: AGTGGTTGTCAGGCGAGGAAAG
NM_005427/TP73	Tumor protein p73	P73	Forward: AGCAGCCCATCAAGGAGGAGTT Reverse: TCCTGAGGCAGTTTGGACACA
NM_000546/TP53	Tumor protein p53 (Li-Fraumeni syndrome)	CYS51STOP/P53	Forward: AGATGGGGTCTCACAGTGTTGC Reverse: ATGTTGACCCTTCCAGCTCCAC
NM_002392/MDM2	MDM2 proto-oncogene, E3 ubiquitin ligase	HDMX/MGC7122 1	Forward: GGGTTCGCACCATTCTCCTG Reverse: GGCAGATGACTGTAGGCCAAGC
NM_152999.3/STAMP 1	STEAP family member 2, metalloreductase (STEAP2),	STEAP2/STAMP1	Forward: ATAGGAAGTGGGGATTTTGC Reverse: AGATGTCTCAGGTCCCACAA

	transcript variant 1		
NM_024636.3/STAMP 2	STEAP family member 4 (STEAP4), transcript variant 1	STEAP4/STAMP2	Forward: GCACTTACACTGCTTGC Reverse: CAGTGGTCAAGCCAGTC
NM_002046/GAPDH	Glyceraldehyde- 3-phosphate dehydrogenase	G3PD, GAPD	Forward: CATTGCCCTCAACGACCACTTT Reverse: GGTGGTCCAGGGGTCTTACTCC